• Disease
  • Radiofrequency Ablation
  • Radiofrequency Ablation In...
  • Key People For Radiofrequency Ablation

    Top KOLs in the world
    Shraga Nahum GOLDBERG†
    radiofrequency ablation liposomal doxorubicin coagulation necrosis
    Luigi Alessandro Solbiati
    liver metastases thermal ablation hepatocellular carcinoma
    Tito Livraghi
    hepatocellular carcinoma percutaneous ethanol injection radiofrequency ablation
    Guy Scott GAZELLE†
    lung cancer united states radiofrequency ablation
    Hyun Chul Rhim
    radiofrequency ablation hepatocellular carcinoma artificial ascites
    Damian Edward Dupuy
    radiofrequency ablation lung cancer irreversible electroporation

    Radiofrequency Ablation in Barrett's Esophagus with Dysplasia


    BACKGROUND: Barrett's esophagus, a condition of intestinal metaplasia of the esophagus, is associated with an increased risk of esophageal adenocarcinoma. We assessed whether endoscopic radiofrequency ablation could eradicate dysplastic Barrett's esophagus and decrease the rate of neoplastic progression.

    METHODS: In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus in a 2:1 ratio to receive either radiofrequency ablation (ablation group) or a sham procedure (control group). Randomization was stratified according to the grade of dysplasia and the length of Barrett's esophagus. Primary outcomes at 12 months included the complete eradication of dysplasia and intestinal metaplasia.

    RESULTS: In the intention-to-treat analyses, among patients with low-grade dysplasia, complete eradication of dysplasia occurred in 90.5% of those in the ablation group, as compared with 22.7% of those in the control group (P<0.001). Among patients with high-grade dysplasia, complete eradication occurred in 81.0% of those in the ablation group, as compared with 19.0% of those in the control group (P<0.001). Overall, 77.4% of patients in the ablation group had complete eradication of intestinal metaplasia, as compared with 2.3% of those in the control group (P<0.001). Patients in the ablation group had less disease progression (3.6% vs. 16.3%, P=0.03) and fewer cancers (1.2% vs. 9.3%, P=0.045). Patients reported having more chest pain after the ablation procedure than after the sham procedure. In the ablation group, one patient had upper gastrointestinal hemorrhage, and five patients (6.0%) had esophageal stricture.

    CONCLUSIONS: In patients with dysplastic Barrett's esophagus, radiofrequency ablation was associated with a high rate of complete eradication of both dysplasia and intestinal metaplasia and a reduced risk of disease progression. (ClinicalTrials.gov number, NCT00282672.)

    Sign-in to see all concepts, it's free!